Clinical Trials

201308040

PARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life; A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer Phase III Principal Investigator Michalski, Jeff Disease Site…

201410102

Positron emission tomography (PET) imaging of poly(ADP-ribose) polymerase (PARP) activity in cancer Phase Early Phase I Principal Investigator Dehdashti, Farrokh Disease Site Colon; Lip, Oral Cavity and Pharynx; Liver; No Disease; Pancreas; Rectum; Unknown Sites…

201508017

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed…

201510089

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological…

201703014

Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel Phase II/III Principal Investigator Michalski, Jeff Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201703178

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer Phase II Principal Investigator Pachynski, Russell Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201704081

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer Phase III (Cancer Control) Principal Investigator Picus, Joel Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201705069

A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk…

201708148

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects Phase II Principal Investigator Picus, Joel Disease Site Prostate Learn more about…

201711133

Phase III randomized “Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma” (AMBASSADOR) versus observation Phase III Principal Investigator Picus, Joel Disease Site Urinary Bladder Learn more about this study at:…

201711182

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer Phase III Principal…

201712023

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer Phase III Principal Investigator Michalski, Jeff Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201801118

A phase I/II study evaluating the safety and efficacy of 23 Gy for high dose rate (HDR) prostate brachytherapy Phase I/II Principal Investigator Gay, Hiram Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201803158

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial Phase II Principal Investigator Picus, Joel Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201807022

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Phase II Principal Investigator Picus, Joel Disease Site Urinary Bladder Learn more about this study at: clinicaltrials.gov

201808043

A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostvac in Metastatic Hormone-Sensitive Prostate Cancer Phase I Principal Investigator Pachynski, Russell Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201808057

A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients with Localized Prostate Cancer Phase II Principal Investigator Pachynski, Russell Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201809005

A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations Phase II Principal…

201810195

A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCnyeso, an HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, as a Single Agent in HLA-A*0201 Positive Patients…

201811079

A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma Phase II Principal Investigator Pachynski, Russell Disease Site Urinary Bladder Learn more about…

201901059

Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer Phase III Principal Investigator Baumann, Brian Disease Site…

201902074

A Phase 1/2 Study to Compare NKTR-214 Combined with Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI alone in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (mRCC) Phase I/II Principal…

201903057

A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE) Phase N/A Principal Investigator Michalski, Jeff Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201903098

A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are 18F-DCFPyL prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naïve, and progressed on…

201903201

Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features Phase II Principal Investigator Gay, Hiram Disease Site Prostate…

201904078

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk…

201904214

IMPACT: Immunotherapy in Patients with Metastatic Cancers and CDK12 Mutations Phase II (Cancer Control) Principal Investigator Reimers, Melissa Disease Site Prostate Learn more about this study at: clinicaltrials.gov

201905101

A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation…

201906051

A Phase II, Open-Label, Multi-dose Study of 89Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Advanced or Metastatic Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the…

201908024

A Pilot Study of Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device Phase N/A Principal Investigator Henke, Lauren Disease Site Anus; Cervix; Colon; Corpus…

201908037

Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)

201908065

A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 Phase I/II Principal Investigator Pachynski, Russell Disease Site Prostate Learn…

201910139

PHASE II STUDY OF CABOZANTINIB IN COMINATION WITH NIVOLUMAB AND IPILIMUMAB IN RARE GENITOURINARY TUMORS Phase II Principal Investigator Picus, Joel Disease Site Kidney; Other Male Genital; Prostate; Urinary Bladder Learn more about this study…

201910162

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer Phase III Principal Investigator Baumann, Brian Disease Site Urinary Bladder Learn more about this study at: clinicaltrials.gov

202002013

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RadiCal)(A031801) Phase II (Cancer Prevention) Principal Investigator Gay, Hiram Disease Site Bones and Joints; Kidney;…

202003013

A Phase 1b Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) in Combination with REGN2810 (anti-PD-1) in Patients with Metastatic or Unresectable Renal Cell Carcinoma (RCC) Phase I Principal Investigator Hsieh, James Disease…

202003048

A Phase 3, Randomized, Double-Blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) Phase III Principal…

202003148

A single arm, multicenter, phase 2 trial to evaluate the efficacy of lenvatinib (LEN) in combination with pembrolizumab (KEYtruda) in subjects with locally advanced or metastatic Non-clear cell renal cell carcinoma (The LENKYN Trial) Phase…

202003164

RANDOMIZED PHASE III TRIAL INCORPORATING ABIRATERONE ACETATE WITH PREDNISONE AND APALUTAMIDE AND ADVANCED IMAGING INTO SALVAGE TREATMENT FOR PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY Phase III Principal Investigator Baumann, Brian Disease Site Prostate…

202007111

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-7386 in Patients with Metastatic Castration-Resistant Prostate Cancer Phase I Principal Investigator Pachynski, Russell Disease Site Metastatic Disease; Prostate Learn…